drug · small molecule

SCEMBLIX

updated 3mo ago

by $NVS NOVARTIS AG🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 7

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for blast phase chronic myelogenous leukemia, bcr-abl1 positive and chronic myelogenous leukemia.

targets

Bcr/Abl fusion protein

all catalysts(0)

nothing on the calendar yet

News(3)

Novartis climbs on upbeat drug sales as key readouts loom
A return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a bigger impact on the company’s long-term outlook.
biopharma_dive · 24d ago
J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch
New data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck leukemia rival and MBX hyperparathyroidism drug hit its goal.
biopharma_dive · 2mo ago
Merck still sees ‘compelling’ outlook for Terns leukemia drug
Despite updated study data that suggest Terns’ treatment may be less differentiated, company executives claimed Thursday that it still could be an important step forward in care.
biopharma_dive · 3mo ago

brand

SCEMBLIX

trade names

Scemblix

generic

ASCIMINIB HYDROCHLORIDE

MOA

12.1 Mechanism of Action Asciminib is an ABL/BCR-ABL1 tyrosine kinase inhibitor. Asciminib inhibits the ABL1 kinase activity of the BCR::ABL1 fusion protein, by binding to the ABL myristoyl pocket. In studies conducted in vitro or in animal models of CML, asciminib showed activity against wild-type BCR::ABL1 and several mutant forms of the kinase, including the T315I mutation.

indication

1 INDICATIONS AND USAGE SCEMBLIX is indicated for the treatment of adult patients with: Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP). This indication is approved under accelerated approval based on major molecular response rate [see Clinical Studies (14.1)] . Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). Previously treated Ph+ CML in CP. Ph+ CML in CP with the T315I mutation. SCEMBLIX is a kinase inhibitor indicated for the treatment of adult patients with: Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP). This indication is approved under accelerated approval based on major molecular response rate. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). ( 1 ) Previously treated Ph+ CML in CP. ( 1 ) Ph+ CML in CP with the T315I mutation. ( 1 )

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 19m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

News(3)

Novartis climbs on upbeat drug sales as key readouts loom

A return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a bigger impact on the company’s long-term outlook.

biopharma_dive · 24d ago

J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch

New data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck leukemia rival and MBX hyperparathyroidism drug hit its goal.

biopharma_dive · 2mo ago

Merck still sees ‘compelling’ outlook for Terns leukemia drug

Despite updated study data that suggest Terns’ treatment may be less differentiated, company executives claimed Thursday that it still could be an important step forward in care.

biopharma_dive · 3mo ago

SCEMBLIX

🐶 often sniffed alongside

targets

all catalysts(0)

News(3)

Report a data issue

comments(0)

SCEMBLIX

🐶 often sniffed alongside

targets

all catalysts(0)

News(3)

Report a data issue

comments(0)